LPV/r — Competitive Intelligence Brief

LPV/r (LPV/r) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (PI) combination. Area: Infectious Disease / Virology.

marketed Protease inhibitor (PI) combination HIV protease Infectious Disease / Virology Small molecule

Target snapshot

LPV/r (LPV/r) — The HIV Netherlands Australia Thailand Research Collaboration. LPV/r is a combination of lopinavir and ritonavir that inhibits HIV protease, preventing the maturation of HIV virions and blocking viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LPV/r TARGET	LPV/r	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Protease inhibitor (PI) combination	HIV protease
continue on current dual boosted PI	continue on current dual boosted PI	Community Research Initiative of New England	marketed	Protease inhibitor (PI) combination with pharmacokinetic booster	HIV protease
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
Fosamprenavir/ritonavir	Fosamprenavir/ritonavir	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (PI) combination class)

1. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class